title: Evidence-based medication adherence in Hispanic patients with systolic heart failure in a disease management program.
abstract: The Hispanic population is the fastest growing minority in the United States, yet there is a paucity of data regarding patient follow-up in heart failure disease management programs (HFDMPs) and evidence-based medication adherence. The purpose of this study is to measure the compliance of evidence-based medication use, specifically measuring angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and beta-blockers (BBs) in the Hispanic population, and compare these data to the white and black population. The authors conducted a cross-sectional study of 561 patients enrolled in an HFDMP at Jackson Medical Hospital in Miami, Florida. At the first visit, 82% of Hispanic, 75% of white, and 79% of black patients were taking ACEIs/ARBs, but only 21% of Hispanic, 35% of white, and 32% of black patients were taking target doses. Hispanic patients are as compliant with ACEI/ARB and BB regimens as are the white and black populations in HFDMPs in a setting of similar socioeconomic features.
authors.affiliation: University of Miami Miller School of Medicine, FL 33136, USA. khebert1@gmail.com
authors.forename: Kathy
authors.initials: K
authors.lastname: Hebert
authors.forename: Julieta
authors.initials: J
authors.lastname: Beltran
authors.forename: Leonardo
authors.initials: L
authors.lastname: Tamariz
authors.forename: Elyse
authors.initials: E
authors.lastname: Julian
authors.forename: Andre
authors.initials: A
authors.lastname: Dias
authors.forename: Pat
authors.initials: P
authors.lastname: Trahan
authors.forename: Lee
authors.initials: L
authors.lastname: Arcement
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D001741:Black or African American / Q000706:statistics & numerical data; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D019468:Disease Management; D019317:Evidence-Based Medicine / Q000706:statistics & numerical data*; D054143:Heart Failure, Systolic / Q000188:drug therapy* / Q000453:epidemiology; D006630:Hispanic or Latino / Q000706:statistics & numerical data*; D006801:Humans; D010342:Patient Acceptance of Health Care / Q000706:statistics & numerical data; D010349:Patient Compliance / Q000706:statistics & numerical data; D015397:Program Evaluation; D014481:United States / Q000453:epidemiology; D044465:White People / Q000706:statistics & numerical data; D016903:Drug Monitoring
chemical_list: D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents